dc.contributor.author | Kibwage, IO | |
dc.contributor.author | Ngugi, JK | |
dc.date.accessioned | 2013-02-20T06:09:47Z | |
dc.date.issued | 2000 | |
dc.identifier.citation | East And Central African Journal Of Pharmaceutical Sciences 3 (2000) 14•19 | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/10365 | |
dc.description.abstract | Sulfadoxine/Pyrimethamine tablets preparations were recently made the first line antimalarial drug. In response to reports on falciparum malaria resistance to such products, sulfadoxine/pyrimethamine tablets in Kenya were evaluated for their in¬vitro performance using tbe parameters of content and dissolution test for the Active Pharmaceutical Ingredient. One brand product had a content of both sulfadoxine and pyrimethamine well below allowed limits. Amongst the brands analysed only 44% had batches that released more than Q = 60% of labelled dose in 30 minutes. Batches of some brands had wide variations in content with some failing the dissolution test. Other brands released less than 60% in 60 minutes. Most brands failed the dissolution test for pyrimethamine and 33% for both sulfadoxine and pyrimethamine. The quality of sulfadoxine/pyrimethamine products on the Kenyan market sbould be a cause for concern to the drug regulatory authority and the Malaria Control Program | en |
dc.language.iso | en | en |
dc.subject | Sulfadoxine/Pyrimethamine, | en |
dc.subject | Content, | en |
dc.subject | Dissolution. | en |
dc.title | Sulphadoxinel/pyrimethamine tablet products on the Kenyan market: Quality Concerns | en |
dc.title.alternative | Quality concerns | en |
dc.type | Article | en |
local.embargo.terms | 6 months | en |
local.embargo.lift | 2013-08-19T06:09:47Z | |